Back to search
FDAFDA · Food and drugs·Recall number D-399-2014

Fenofibric Acid, immediate release tablet, 35 mg, 30 count bottle Rx only, Mutual Pharmaceutical Co., Inc., Philadelphia, PA 19124 USA NDC 53489-677-07

Published January 15, 2014 · Recall initiated: February 27, 2013

Summary

FDA records drug Class III recall D-399-2014, published January 15, 2014 and initiated February 27, 2013. Recalling firm: Mutual Pharmaceutical Company, Inc.; Status: Terminated; Lot: Lot 6561703, exp. 03/14. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Labeling: Incorrect instructions; an error in section 5.11 of the patient insert that results in incorrect medical advice. Specifically, the labeling should read "If a severely depressed HDL-C level is detected, fibrate therapy should be withdrawn, and the HDL-C level monitored until it has returned to baseline, and fibrate therapy should not be re-initiated." The labeling for the recalled lots

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Mutual Pharmaceutical Company, Inc.
Distributor
Nationwide and Puerto Rico.
Lot
Lot 6561703, exp. 03/14
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Fenofibric Acid, immediate release tablet, 35 mg, 30 count bottle Rx only, Mutual Pharmaceutical Co., Inc., Philadelphia, PA 19124 USA NDC 53489-677-07 recalled?

Yes. FDA published recall D-399-2014 on January 15, 2014. Reported hazard: Labeling: Incorrect instructions; an error in section 5.11 of the patient insert that results in incorrect medical advice. Specifically, the labeling should read "If a severely depressed HDL-C level is detected, fibrate therapy should be withdrawn, and the HDL-C level monitored until it has returned to baseline, and fibrate therapy should not be re-initiated." The labeling for the recalled lots

What should I do if I have this product?

Voluntary: Firm initiated · Letter